MET and hepatocellular carcinoma: For instance, AMG 337, a potential and highly selective small molecule Met kinase inhibitor, significantly decreases tumor growth of Met-high-expression and Met-amplified HCC cell lines in in vitro and in vivo trials (Du et al., 2016).